Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

Background: In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release.

Aims: To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release.

Method: ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial.

Transcutaneous vagus nerve stimulation improves emotional processing.

Background: Invasive vagus nerve stimulation (iVNS) is approved for the treatment of major depressive disorder (MDD). The limited understanding of its underlying mechanisms, however, hinders stratification and the prediction of treatment response. Given the strong projections of the afferent vagal nucleus to brain regions involved in emotional processing, we tested whether acute transauricular VNS (taVNS) can improve emotional processing that is a core deficit in MDD.

Resilience to major life events: Advancing trajectory modeling and resilience factor identification by controlling for background stressor exposure.

Resilience has been defined as the maintenance or quick recovery of mental health during and after stressor exposure. One popular operationalization of this concept is to model prototypical trajectories of mental health in response to an adverse event, where trajectories of undisturbed low or rapidly recovering symptoms both comply with the resilience definition. However, mental health responses are likely also influenced by other stressors occurring before or during the observation time window.